Oncomed, a subsidiary of the German pharmaceutical company medac GmbH, is a leading manufacturer of high-quality cytostatic injections for the treatment of cancer patients. With its expertise in contract development and manufacturing (CDMO), Oncomed specializes in supplying highly effective cytotoxic drugs globally. The company offers a range of specialized technologies, including the handling of highly active APIs, disposable systems, and sensitive API handling.

Oncomed understands the pressures faced by pharmaceutical companies in terms of cost and timely delivery, and therefore provides flexible, accessible, and fast outsourcing services tailored to meet the specific requirements of each customer. The company boasts two production lines and continuously invests in expanding its production capacity and state-of-the-art technologies. In addition, Oncomed places great importance on transparent processes, reducing the need for additional investments to a minimum.

The company's employees are driven by their skills, flexible approach, and commitment to finding solutions to meet even the most ambitious customer demands. With Oncomed, customers can expect innovative and advanced solutions for highly effective medicines